Figures & data
Figure 1. The chemical structures of (A) syringolin A (SylA), (B) syringolin B (SylB), (C) glidobactin A (GlbA), and (D) syringolin B analogue TIR-203.
Figure 2. Syringolin B-analogue TIR-203 inhibits the proliferation of human multiple myeloma (MM) cells and human neuroblastoma (NB) cells. (A) MM.1R cells and (B) MYCN2 cells were treated over a period of 24 h with natural product derived syringolin B-analogue TIR-203 at various concentrations (0–10 µM). SylA and bortezomib (Btz) were used as controls for comparison. The viability of cells is expressed as percent (%) cell survival relative to untreated control cells and was determined by MTS assay as outlined in the material and methods.
Figure 3. Inhibitory effects of syringolin B-analogue TIR-203 on proteasomal activity in multiple myeloma (MM) cells and neuroblastoma (NB) cells. The (A) chymotrypsin-like (CT-L), (B) caspase-like (C-L), and the trypsin-like (T-L) proteolytic activities of MM.1R and MYCN2 cells were measured. Cells were treated over a period of 2 h with natural product derived syringolin B-analogue TIR-203 at various concentrations (0–10 µM). SylA and bortezomib (Btz) were used as controls for comparison. The proteasomal activities were measured as outlined in the material and methods section.
